Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

Bellahcène, Akeila; Riet, Ivan Van; Greef, Catherine De; Antoine, Nadine; Young, M.F.; Camp, Ben Van; Castronovo, Vincent

doi:10.1111/j.1365-2141.2000.02506.x

Cited by 4 publications

(2 citation statements)

References 11 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was suggested that BSP protein expression in primary resected NSCLC was strongly associated with BM progression and could be useful in identifying patients at high risk of developing BM. Bellahcene et al [7,9] also reportedthatBSPwashighlyexpressedindifferenthistologicaltypesoflungcancerbothinproteinandmRNAanalysis.…”

Section: Serum Levels Of Bsp Cea and Cyfra 21-1mentioning

confidence: 99%

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Zhi²,

Li³

2011

Onkologie

View full text Add to dashboard Cite

Background: The purpose of this study was to evaluate the diagnostic and prognostic significance of serum bone sialoprotein (BSP) in patients with bone metastasis (BM) from non-small cell lung cancer (NSCLC). Patients and Methods: A total of 146 patients diagnosed with NSCLC and 110 healthy controls were enrolled in this study. The clinical characteristics including clinical stage, pathological type, smoking status, and ECOG performance status were obtained. The mean serum BSP was detected by sandwich ELISA. Results: The mean serum BSP level in individuals with BM was significantly higher than those in non-BM NSCLC and controls (p < 0.001). Receiver operating characteristics (ROC) analysis showed that BSP discriminated patients with BM from non-BM NSCLC patients at the cutoff value of 33.56 ng/ml. Sensitivity and specificity were 77.8 and 81.1%, respectively. Kaplan-Meier analysis showed that subjects with higher BSP levels had a shorter BM-free period than those with lower BSP levels. Cox regression analysis revealed that the BSP level was a predictor for prognosis of BM from NSCLC. Conclusion: Serum BSP is a useful biomarker for the diagnosis of BM from NSCLC, and can be regarded as an independent factor for predicting the prognosis of BM from NSCLC.

show abstract

Section: Serum Levels Of Bsp Cea and Cyfra 21-1mentioning

confidence: 99%

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Zhi²,

Li³

2011

Onkologie

View full text Add to dashboard Cite

show abstract

“…Measurement of cell surface receptors and protein expression (19) and genetic profiling of the primary tumor may be informative, but conference participants were not optimistic that such approaches would provide clinically useful information in the next 5 years. More reliable prediction will require study of the target organ for metastasis rather than the primary lesion, as well as a better understanding of the bone microenvironment and the interactions between tumor cells, bone cells, and marrow stromal cells.…”

Section: Preserving Normal Bone Healthmentioning

confidence: 99%

Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference

Coleman

Guise

Lipton

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bonetargeted therapies. Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.Tumor metastasis to the skeleton affects over 400,000 individuals in the United States annually, more than any other site of metastasis, including significant proportions of patients with breast, prostate, lung, and other solid tumors (1). At present, once cancer metastasizes to bone, it is incurable and can cause severe morbidity and mortality. Bone metastases are often associated with skeletal-related events (SRE), which include severe pain, bone fractures, need for radiation therapy to bone, need for surgery to bone, spinal cord compression, and bone demineralization. Bisphosphonate therapy, the current standard of care for metastatic bone cancer, has been shown to decrease the risk of SREs by up to 50% and slow the rate of development of SREs (2). Although this therapeutic advance is of major clinical significance, bisphosphonate therapy does not completely block bone metastasis. In addition, bisphosphonate therapy is occasionally associated with renal toxicity and osteonecrosis of the jaw. Thus, new strategies are needed to develop bone-targeted agents to both

show abstract

Bone niche and bone metastases

Han

Kang

2022

Bone Cancer

View full text Add to dashboard Cite

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

Cited by 4 publications

References 11 publications

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Predictive Value of Serum Bone Sialoprotein in Patients with Bone Metastasis of Non-Small Cell Lung Cancer

Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference

Bone niche and bone metastases

Contact Info

Product

Resources

About